University of Washington, Department of Internal Medicine, Seattle, Washington.
Translational Genomics Research Institute (TGen), University of Arizona Cancer Center, Tucson, Arizona.
Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1.
Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. .
尽管治疗方法取得了重大进展,但癌症仍然是导致死亡的主要原因之一。此外,传统疗法的毒性对耐受性和依从性构成了重大挑战。TTFields 是一种非侵入性的抗癌治疗方式,利用特定频率和强度的交替电场选择性地破坏癌细胞的有丝分裂。TTFields 靶向细胞周期中至关重要的蛋白质,导致有丝分裂停滞和细胞凋亡。TTFields 还促进抗肿瘤免疫反应。TTFields 在多形性胶质母细胞瘤 (GBM) 患者中的临床试验已证明安全有效,已获得 FDA 批准用于新诊断和复发性 GBM 的治疗。其他局部实体肿瘤的试验正在进行中。